DK1487828T3 - Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme - Google Patents

Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme

Info

Publication number
DK1487828T3
DK1487828T3 DK03745294T DK03745294T DK1487828T3 DK 1487828 T3 DK1487828 T3 DK 1487828T3 DK 03745294 T DK03745294 T DK 03745294T DK 03745294 T DK03745294 T DK 03745294T DK 1487828 T3 DK1487828 T3 DK 1487828T3
Authority
DK
Denmark
Prior art keywords
morpholinyl
treatment
inflammatory diseases
urea derivatives
urea
Prior art date
Application number
DK03745294T
Other languages
English (en)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1487828T3 publication Critical patent/DK1487828T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK03745294T 2002-03-28 2003-03-27 Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme DK1487828T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
PCT/EP2003/003335 WO2003082861A2 (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
DK1487828T3 true DK1487828T3 (da) 2009-02-02

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03745294T DK1487828T3 (da) 2002-03-28 2003-03-27 Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme

Country Status (23)

Country Link
US (1) US7622464B2 (da)
EP (1) EP1487828B1 (da)
JP (1) JP4465195B2 (da)
KR (1) KR20040093488A (da)
CN (1) CN1656092A (da)
AR (1) AR040403A1 (da)
AT (1) ATE413399T1 (da)
AU (1) AU2003226757A1 (da)
BR (1) BR0308780A (da)
CA (1) CA2480106A1 (da)
CY (1) CY1108652T1 (da)
DE (1) DE60324535D1 (da)
DK (1) DK1487828T3 (da)
ES (1) ES2315519T3 (da)
IL (1) IL164047A0 (da)
IS (1) IS7444A (da)
MX (1) MXPA04009459A (da)
NO (1) NO20044448L (da)
PT (1) PT1487828E (da)
RU (1) RU2004127928A (da)
SI (1) SI1487828T1 (da)
TW (1) TW200400035A (da)
WO (1) WO2003082861A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
ES2564167T3 (es) * 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
TW200619212A (en) 2004-09-08 2006-06-16 Mitsubishi Pharma Corp Morpholine derivatives
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
ES2663517T3 (es) 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
US20230271983A1 (en) * 2020-07-29 2023-08-31 Universidade De Santiago De Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
EP0759918A1 (en) 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
AU702307B2 (en) 1994-07-20 1999-02-18 Altana Pharma Ag Piperazinothiopyridines for the control of helicobater bacteria
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO2000018767A2 (en) 1998-09-30 2000-04-06 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases

Also Published As

Publication number Publication date
ES2315519T3 (es) 2009-04-01
MXPA04009459A (es) 2005-01-25
CA2480106A1 (en) 2003-10-09
CY1108652T1 (el) 2014-08-13
AU2003226757A1 (en) 2003-10-13
WO2003082861A2 (en) 2003-10-09
JP4465195B2 (ja) 2010-05-19
NO20044448L (no) 2004-10-26
BR0308780A (pt) 2004-12-28
ATE413399T1 (de) 2008-11-15
KR20040093488A (ko) 2004-11-05
IL164047A0 (en) 2005-12-18
US7622464B2 (en) 2009-11-24
SI1487828T1 (sl) 2009-04-30
RU2004127928A (ru) 2005-06-27
JP2005526815A (ja) 2005-09-08
WO2003082861A3 (en) 2004-03-11
DE60324535D1 (de) 2008-12-18
CN1656092A (zh) 2005-08-17
PT1487828E (pt) 2009-01-06
AR040403A1 (es) 2005-04-06
IS7444A (is) 2004-09-13
EP1487828B1 (en) 2008-11-05
EP1487828A2 (en) 2004-12-22
TW200400035A (en) 2004-01-01
US20060063765A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20044054L (no) Administrering av midler for behandling av betennelse
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK1885380T3 (da) Natriummetaarsenit til anvendelse til behandling af metastatiske neoplastiske sygdomme
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DK1597171T3 (da) Terapeutisk mikroskum
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
NO20050689L (no) Terapeutisk anvendelse
DK1503747T3 (da) Diclofenacbaseret sammensætning til topisk behandling af sygdomme
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer